Suven Life Sciences’ drug SUVN-502 completes all chronic toxicological studies

18 May 2011 Evaluate

Suven Life Sciences’ clinical drug candidate SUVN-502 has completed all the long term chronic studies like 6-month rat toxicological (tox), 9-month dog tox and developmental tox studies like prenatal development tox in rats and rabbits, embryo-fetel development tox in rats and male fertility tox in rats very successfully and demonstrated very high margin of safety (MOS). These regulatory tox studies are essential for FDA approval to initiate human phase 2a clinical trials in patient population.

SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested with excellent bioavailability. The next stage of testing will be proof of concept phase 2a clinical trials in patients with Alzheimer’s/Schizophrenia disease.

Suven Life Sciences Share Price

170.15 -1.25 (-0.73%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×